The Bod share price was flying today as the company announced its entrance into the Netherlands market. We take closer look.
The post BOD (ASX:BDA) share price soars 8% on product launch appeared first on Motley Fool Australia. –
The BOD Australia Ltd (ASX: BDA) share price was shooting higher as the company launched its CBD (cannabidiol) product in the Netherlands. By the market’s close, the BOD share price was trading 7.69% higher at 56 cents.
The Australian micro-cap has been on an impressive run as of late, gaining 75% so far this year.
What BOD does
BOD is a vertically integrated (loosely meaning it does everything itself) distributor of plant-based natural health supplements and beauty solutions. BOD partnered with Australian vitamin giant Swisse in July last year.
The company has a cannabis business and is developing a range of over the counter and therapeutic products based on certified cannabis extracts.
The BOD share price was flying today as the company announced it has launched its four new CBD products in the Netherlands. The products were released under recognised Australian vitamin and skincare brand Swisse Wellness.
The CBD products are in soft, gel-cap form and are designed to target specific need states including immune function and joint mobility.
The entry into the Netherlands marks the third major market entry for BOD consumer CBD products. The cannabis producer currently has sales channels established in Australia, the United Kingdom and the Netherlands. Furthermore, BOD is planning more expansion into the European market which is estimated to be worth upwards of 450 million euros.
CEO of the company, Jo Patterson, was pleased as she said:
Together with H&H, we have now collaboratively launched Swisse-products into three major markets in a very short space of time and the Company is confident that our highquality CBD products will be well received by consumers to address a range of mainstream need states.
What now for the BOD share price?
The BOD share price rose almost 8% today on the back of the impressive announcement. However, according to the release, there could be more news in store for holders of the cannabis company’s shares.
This is because BOD also disclosed it is now focused on progressing its United States market entry, with the first binding purchase orders for products expected later this quarter.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- CSL (ASX:CSL) share price and 2 other ASX stocks among latest broker “buy” ideas
- Why the Weebit (ASX:WBT) share price soared 24% Tuesday
- Centuria Capital (ASX:CNI) delivering on FY21 strategy
- Zip (ASX:Z1P) announces major payments expansion with Tap & Zip
- Apiam (ASX:AHX) share price soars 12% on strong Q1 update
Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.